Dasabuvir : a new direct antiviral agent for the treatment of hepatitis C.

Article Details

Citation

Copy to clipboard

Trivella JP, Gutierrez J, Martin P

Dasabuvir : a new direct antiviral agent for the treatment of hepatitis C.

Expert Opin Pharmacother. 2015 Mar;16(4):617-24. doi: 10.1517/14656566.2015.1012493. Epub 2015 Feb 9.

PubMed ID

25665437 [ View in PubMed

]

Abstract

INTRODUCTION: Treatment of hepatitis C virus (HCV) infection with direct-acting antivirals (DAAs) has revolutionized the care of infected patients. Among these novel compounds are non-nucleoside analogs, which bind viral RNA-dependent RNA polymerase resulting in a conformational change inhibiting RNA synthesis. AREAS COVERED: Efficacy and tolerability of treatment regimens containing the non-nucleoside analog polymerase inhibitor dasabuvir (ABT-333). EXPERT OPINION: Dasabuvir-containing regimens achieve high rates of sustained virologic response in HCV genotype 1a and 1b-infected patients when combined with other DAAs, namely paritaprevir (ABT-450), ritonavir and ombitasvir (ABT-267). In the populations studied, dasabuvir seems to be well tolerated and safe. The major limitations of this novel drug are its genotype-restricted activity, the necessity to include ribavirin for HCV genotype 1a and the emergence of resistance if not combined with other DDAs.

DrugBank Data that Cites this Article

Drugs

Dasabuvir

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Dasabuvir	Nonstructural protein 5B (NS5B)	Protein		Yes	Inhibitor	Details